BioCentury | Jul 21, 2020
Product Development

First inhaled interferon COVID-19 readout bolsters case for class, but more robust data needed

Data suggesting an inhaled IFNB1 product from Synairgen can reduce the chance a patient with COVID-19 develops severe disease gave a jolt to the biotech’s shares Monday, but more statistically robust data are still needed...
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

NextCure Inc. (NASDAQ:NXTC) said CMO Kevin Heller has resigned, effective Aug. 4, to pursue a new opportunity; the immunotherapy company is searching for a successor. NextCure also said Monday that, based on response data, it...
BioCentury | Jul 1, 2020

June 30 Quick Takes: Another first for Ultragenyx; plus approvals for Genentech’s Phesgo, Keytruda, Bavencio and Ultomiris

Ultragenyx’s Dojolvi wins FDA approval for rare disease FDA approved Dojolvi triheptanoin (UX007) from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to treat long-chain fatty acid oxidation disorders, making it the first drug approved for the indication. The...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

Novavax Inc. (NASDAQ:NVAX), which expects Phase I data for its COVID-19 vaccine in July, hired Filip Dubovsky as SVP and CMO. He succeeds CMO Louis Fries, who has retired. Dubovsky was head of clinical engagement...
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

iTeos Therapeutics S.A. made several hires Tuesday, including Matthew Gall as CFO and Yvonne McGrath as VP of R&D. Gall was SVP of corporate development at Sarepta Therapeutics Inc. (NASDAQ:SRPT); McGrath was CSO of Complix...
BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

Brain cancer CAR T therapy  A McMaster University and University of Toronto team revealed in a Cell Stem Cell paper proof-of-concept data for Empirica Therapeutics’ lead product eCAR-133, a CAR T cell therapy targeting PROM1....
BioCentury | May 6, 2020

FDA approval of Novartis’ capmatinib heralds arrival of new targeted lung cancer therapies

FDA’s approval of the c-MET inhibitor Tabrecta capmatinib from Novartis is the first for a series of targeted non-small cell lung cancer therapies expected to reach the market this year. It’s also the first approval...
BioCentury | May 4, 2020
Product Development

Investors see little value in remaining Newron programs following Rett syndrome failure

The failure of Newron’s sarizotan in Rett syndrome leaves the company with two pipeline programs, but its valuation is now trading near its cash position -- a sign that investors see little value in what...
BioCentury | May 2, 2020
Product Development

Daily Chart: Oxford’s global network of COVID-19 vaccine manufacturing sites

To meet demand as much demand for its COVID-19 vaccine as quickly as possible, the University of Oxford has been building a coalition of manufacturing partners before it even knows if the vaccine works. The...
Items per page:
1 - 10 of 2563